BH-Pilot results will be presented in this October

Biohope will present a poster in the framework of the BST (Basic Science in Transplantation) congress that takes place from October 11th to 13th in Rotterdam. It shows the biotechnological principles of the Immunobiogram (IMBG) and the results of the clinical study BH-Pilot, in which the IMBG was tested in 70 patients with a renal transplant (RT) of more than one year of evolution. The BH-Pilot Study was also recently presented at the  European Congress Immunology 2018.

The IMBG determines the potential utility of the 7 immunosuppressants most commonly used in RT to inhibit the immune response in each patient and allows to obtain an individualized profile of sensitivity / resistance to these drugs, so it has the potential to become a useful tool to establish the most adequate drugs when adjusting the immunosuppressant treatment of each patient.

IMBG mimics the immune stimulation profile in patients with RT. Our immunoassay is performed with a patient’s blood sample and physiologically stimulated immune cells (PBMC). The stimulated PBMCs are distributed in channels where the action of the different immunosuppressants (IMS) is exposed, which differ from a disc at the end of each channel. Each IMS exerts an inhibitory action on the activation and proliferation of immune cells, which can be quantified by using a reagent that emits fluorescent signals and transformed into a response curve by a mathematical model.

The application of the IMBG in BH-Pilot showed that 55% of the patients with poor clinical evolution presented a pattern of resistance to some of the IMS that they were taking.

The IMBG may allow physicians to select a personalized treatment for each person who has undergone a kidney transplant, thus decreasing the risk of rejection of the transplanted organ.

2018-10-04T17:06:35+00:00October 2nd, 2018|ON THE MOVE|0 Comments